Главная › Немелкоклеточный рак легкого › Арканзас

Клинические исследования Немелкоклеточный рак легкого в штате Арканзас

34 исследований по теме Немелкоклеточный рак легкого ищут участников в центрах в штате Арканзас.

Города в штате Арканзас

Официальный текст исследования (на английском)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT04267848

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 2 окт. 2026 г. · NCT07293247

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Highlands Oncology Group - Springdale /ID# 277132, Springdale

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT07155187

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT06498635

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Highlands Oncology Group, PA, Fayetteville
Highlands Oncology Group, PA, Rogers
Highlands Oncology Group, PA, Springdale
и еще 1

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 28 сент. 2026 г. · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060), Little Rock
Highlands Oncology Group-Research Department ( Site 0062), Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Highlands Oncology Group, Fayetteville
Highlands Oncology Group, Rogers
Highlands Oncology Group, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07222566

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Highlands Oncology Group, PA, Fayetteville
Highlands Oncology Group, PA, Rogers
Highlands Oncology Group, PA, Springdale

Набор участниковФаза 1/2

Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT07227298

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Highlands Oncology Group, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT06890598

Pan-tumor MRD Study

CARTI, Little Rock
Highlands Oncology Group (HOG), Springdale

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT06605404

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Mercy Hospital Fort Smith, Fort Smith
CARTI Cancer Center, Little Rock

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 24 сент. 2026 г. · NCT03191149

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Little Rock
Research Site, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 23 сент. 2026 г. · NCT06357533

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site, Little Rock

Набор участниковФаза 2

Возраст от 18 до 95 · Любой пол · Обновлено 23 сент. 2026 г. · NCT05061550

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

University of Arkansas for Medical Sciences /ID# 272923, Little Rock

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06568939

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0686, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06875310

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 18 сент. 2026 г. · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site, Hot Springs
Clinical Study Sites, Jonesboro

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 18 сент. 2026 г. · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Highlands Oncology Group - Springdale, Springdale

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 16 сент. 2026 г. · NCT04613596

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Highlands Oncology Group, Springdale

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 8 сент. 2026 г. · NCT06119581

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006), Little Rock

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 3 сент. 2026 г. · NCT06422143

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

University of Arkansas for Medical Sciences, Little Rock

Набор участниковФаза 3

Возраст от 18 лет · Любой пол · Обновлено 17 авг. 2026 г. · NCT06500481

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

University of Arkansas, Little Rock

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 5 авг. 2026 г. · NCT07444814

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

Highlands Oncology Group, Springdale

Набор участниковФаза 3

Возраст от 18 до 90 · Любой пол · Обновлено 27 июл. 2026 г. · NCT06745908

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Highlands Oncology Group, Fayetteville
Highlands Oncology Group, Rogers
Highlands Oncology Group, Springdale

Набор участниковФаза 1

Возраст от 18 лет · Любой пол · Обновлено 6 июл. 2026 г. · NCT04389632

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

Mercy Hospital - FTS, Fort Smith

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 29 июн. 2026 г. · NCT07327489

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
University of Arkansas for Medical Sciences, Little Rock

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 3 июн. 2026 г. · NCT05642572

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site, Fayetteville

Набор участниковФаза 3

Возраст от 18 до 130 · Любой пол · Обновлено 14 мая 2026 г. · NCT06417814

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
University of Arkansas for Medical Sciences, Little Rock

Набор участниковФаза 2

Возраст от 18 лет · Любой пол · Обновлено 6 мая 2026 г. · NCT06116682

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro
University of Arkansas for Medical Sciences, Little Rock

Набор участниковФаза 2

18 Minutes · Любой пол · Обновлено 5 мая 2026 г. · NCT06031688

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro

Набор участниковФаза 2/3

Возраст от 18 лет · Любой пол · Обновлено 5 мая 2026 г. · NCT06616584

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Mercy Hospital Fort Smith, Fort Smith
NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 17 мар. 2026 г. · NCT06418204

GEMINI-NSCLC: NSCLC Biomarker Study

Mercy Clinic Oncology - Fort Smith, Fort Smith

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 5 февр. 2026 г. · NCT05236114

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio SYNERGY-AI site, Little Rock

Набор участниковНаблюдательное исследование

Любой возраст · Любой пол · Обновлено 28 окт. 2025 г. · NCT03452774

BostonGene and Exigent Genomic INsight Study

Highlands Oncology Group, Rogers

Набор участниковНаблюдательное исследование

Возраст от 18 лет · Любой пол · Обновлено 17 февр. 2025 г. · NCT06272864

Источник: ClinicalTrials.gov, данные получены 5 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.